



SP 1643

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

194

In re Application of: Uffe Loevborg

Serial No.: 09/056,343

Filed: April 7, 1998

Group Art Unit: 1643

Evaminary to be assigned

Examiner: to be assigned

AUG -3 PH 8:

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

For: Proteins with Changed Epitopes and Methods for the Production Thereof

Assistant Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Information Disclosure Statement
- 2. PTO-1449 Form
- 3. Copy of References

WED AM 7:55 JP 180

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks Washington, DC 20231

on July 28, 1998.

Miriam Kelly

(name of person mailing paper)

(signature of person mailing paper)



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loevborg

Serial No.: 09/056,343

Group Art Unit: 1643

Filed: April 7, 1998

Examiner: William Moore

For: Proteins with Changed Epitopes and Methods for the Production Thereof

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Collins et al., Clinical and Experimental Allergy, Vol. 26, pp. 36-42 (1996)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record

therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: July 28, 1998

Carol E. Rozek, Reg. No. 36,993 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123